Diabetes, obesity & metabolism|2025|Unknown authors
PMID: 40832789
A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
Therapeutic innovation in cardiovascular medicine is rapidly overcoming the limitations of conventional strategies, providing more targeted, durable, and multidimensional solutions. Key advances include next-generation lipid-lowering agents such as P…
Introduction This study aims to evaluate the risk of residual gastric content (RGC) among patients taking semaglutide/tirzepatide undergoing an esophagogastroduodenoscopy (EGD). Methods A retrospective observational study was conducted from 2024 to 2…
BACKGROUND: While cardiovascular benefits of tirzepatide, a glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes mellitus (T2DM), and its comparative effectiveness vs glucagon-like peptide…
We present the case of a 52-year-old woman who developed a functional small bowel obstruction despite having no history of abdominal surgery, prior bowel obstruction, or GI interventions. The only notable recent change in her medical history was a do…
Research on Glucagon-like peptide 1 receptor agonist (GLP-1RA) has mainly focused on the efficacy of weight loss and not the long-term efficacy of weight loss maintenance. This systematic review and meta-analysis aims to evaluate the sustainability o…
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory disease associated with obesity and metabolic dysregulation. Current therapies yield variable benefits and do not target metabolic drivers. Tirzepatide, a dual GLP-1/GIP receptor ago…
OBJECTIVE: Aim: To examine potential protective effect of Tirzepatide against obesity-induced metabolic dysfunction and hepatic inflammatory and apoptotic responses. PATIENTS AND METHODS: Materials and Methods: A total of 28 adult male Sprague-Dawley…
Obstructive sleep apnea (OSA) is a sleep disorder commonly secondary to obesity that has detrimental effects on health and quality of life. Thus, weight loss is one of the mainstays of OSA treatment. Tirzepatide, a novel glucagon-like peptide-1 (GLP-…
AIMS: This analysis evaluated whether gastrointestinal (GI) adverse events (AEs) including nausea, vomiting, diarrhoea (N/V/D) and dyspepsia were associated with weight reduction with tirzepatide across the SURMOUNT-1 to -4 trials. MATERIALS AND METH…
OBJECTIVE: To explore the relationship between metabolic and histological responses in a phase 2 trial of tirzepatide in metabolic dysfunction-associated steatohepatitis (MASH). RESEARCH DESIGN AND METHODS: This is a participant-level post hoc analys…
BACKGROUND: Obesity, a pervasive global health challenge affecting more than 2 billion people, requires comprehensive interventions. Traditional approaches, including lifestyle modification, and diverse drugs targeting a gastrointestinal hormone, inc…
The SUMMIT trialshowed that the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide improves quality of life and reduces worsening heart failure (HF) events in patients with HF with preserved ejection fracti…